Global Blood Therapeutics, Inc.
(NASDAQ GS: GBT)
Rigrodsky Law, P.A. is investigating Global Blood Therapeutics, Inc. (“Global Blood”) regarding possible breaches of fiduciary duties and other violations of law related to Global Blood’s agreement to be acquired by Pfizer Inc. Under the terms of the agreement, Global Blood’s shareholders will receive $68.50 per share.